International Medical Journal, Vol. 28., Iss. 1, 2022, P. 5−10.
FEATURES OF CONTENT OF ENERGY AND ADIPOKINE METABOLIС INDICATORS IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION AND COMORBIDITIES AFTER PRIMARY STENTING OF CORONARY ARTERIES
Kharkiv National Medical University, Ukraine
To date, it is important to study the energy and adipokine metabolism indicators for the patients with acute myocardial infarction in the comorbid pathology presence. To determine the content of energy and adipokine metabolism in the patients with ST−segment elevation, depending on the presence or absence of obesity in the hospital period after primary coronary artery stenting, 120 patients were surveyed. They were divided into groups depending on the presence of comorbid pathology, i.e. obesity. Adropine, irisin, fatty acid binding protein 4 (FABP−4), C1q / TNF−associated protein 3 (CTRP 3) were examined by enzyme−linked immunosorbent assay. All patients underwent coronary angiography. According to the study results, a decrease in the content of adropine, irisin and CTRP 3 as well as an increase in the concentration of FABP 4 on the first and fourteenth days in the patients of both groups compared with the control group (p ˂ 0.05) were determined. In the group of patients with myocardial infarction without obesity, an inverse correlation between Syntax Score (SS) and adropine (r = −0.432, p = 0.01), irisin (r = −0.478, p < 0.01), CTRP 3 r = − 0.473, p < 0.01), positive correlation between SS and FABP 4 (r = 0.436, p <0.05) were found. In the obese group, there was an inverse relationship between SS and adropine (r = −0.412, p < 0.05), irisin (r = −0.475, p < 0.05), CTRP 3 (r = −0.427, p < 0.05) and a direct relationship between SS and FABP 4 (r = 0.428, p < 0.05). The findings showed that obese patients with myocardial infarction had better energy and adipokine metabolism than obese patients. It was concluded that changes in energy and adipokine profiles in the patients might be a prognostic marker of the effectiveness of treatment of acute myocardial infarction in the comorbidity presence.
Key words: energy and adipokine exchange, myocardial infarction, obesity, stenting.
1. WHO Newsletter: 10 leading causes of death in the world. URL: https://www.who.int/ ru/news−room/fact−sheets/detail/the−top−10−causes−of−death
2. WHO Newsletter: obesity and overweight. URL: https://www.who.int/ru/news−room/fact−sheets/detail/obesity−and−overweight
3. Skybchik V. A., Melen Y. P. Clinical course and remodeling of left ventricle in patients with ST segment elevention acute myocardial infarction after primary coronary artery stenting. Cardiac Surgery and Interventional Cardiology. 2019. Vol. 1, № 24. P. 21−28. doi: http://doi.org/10.31928/2305−3127−2019.1.2128
4. Targeting cardiac metabolic pathways: a role in ischemic management vascular health and risk management / A. S. Yehualashet et al. Vascular Health and Risk Management. 2020. Vol. 16. P. 353−365. doi: https://doi.org/10.2147/ VHRM.S264130
5. The role of adipokines in cardiovascular disease / R. Shibata et al. J. of Cardiology. 2017. Vol. 70, № 4. P. 329−334. doi: https://doi.org/10.1016/j.jjcc.2017.02.006
6. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST−segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST−segment elevation of the European Society of Cardiology (ESC) / B. Ibanez et al. Eur. Heart J. 2018. Vol. 39. P. 119−177. doi: https://doi.org/10.1093/eurheartj/ehx393
7. Yumuk V. European guidelines for obesity management in adults. Obes. Facts. 2015. Vol. 8. P. 402−424. doi: https://doi.org/10.1159/000442721
8. Schutza D. D. European practical and patient centred guidelines for adult obesity management in primary care. Obes. Facts. 2019. Vol. 12. P. 40−66. doi: https://doi.org/10.1159/ 000496183
9. 2018 ESC/EACTS Guidelines on myocardial revascularization / F.−J. Neumann et al. European Heart J. 2019. Vol. 40. P. 87−165. doi: https://doi.org/10.1093/eurheartj/ehy394
10. Kal'kulyator SYNTAX Score URL: http://www.syntaxscore.com/
11. Radchenko O. M., Priimachok O. O. Osobennosti porazheniya koronarnykh arterii u bol'nykh s ostrym infarktom miokarda. Bukovins'kii medichnii vіsn. 2015. T. 19, № 3. S. 144−146.
12. Ertem A. G. Association between serum adropin level and burden of coronary artery disease in patients with non−ST elevation myocardial infarction. Anatol. J. Cardiol. 2017. Vol. 17, № 2. P. 119−124. doi: https://doi.org/10.14744/anatoljcardiol.2016.7149
13. An analysis on coronary artery disease severity with serum adropin level in patients with acute ST−segment elevation myocardial infarction / M. Öztürk et al. Sakarya Med. J. 2020. Vol. 10, № 4. P. 623−628. doi: https://doi.org/10.31832/smj.767212
14. Association of circulating irisin levels and the characteristics and prognosis of coronary artery disease / Jian−An Pan et al. Am J. Med. Sci. 2021. Vol. 362, № 1. P. 63−71. doi: https://doi.org/10.1016/j.amjms.2021.02.020
15. Serum irisin level can predict the severity of coronary artery disease in patients with stable angina / T. H. Efe et al. Korean Circ. J. 2017. Vol. 47, № 1. P. 44−49. doi: https://doi.org/10.4070/kcj.2016.0079
16. Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction / M. Obokata et al. Eur. Heart J.: Acute Cardiovascular Care. 2016. Vol. 7, № 6. P. 561−569. doi: https://doi.org/ 10.1177/2048872616683635
17. Serum adipocyte fatty acid−binding protein is independently associated with complex coronary lesions in patients with stable coronary artery disease / M. Kajiya et al. Heart and Vessels. 2012. Vol. 28, № 6. P. 696−703. doi: https://doi.org/ 10.1007/s00380−012−0310−1
18. Sawicka M., Janowska J., Chudek J. Potential beneficial effect of some adipokines positively correlated with the adipose tissue content on the cardiovascular system. International J. of Cardiology. 2016. Vol. 222. P. 581−589. doi: https://doi.org/10.1016/j.ijcard.2016.07.054
19. The C1q/TNF−related proteins (CTRPs) in pathogenesis of obesity−related metabolic disorders: Focus on type 2 diabetes and cardiovascular diseases / M. Shanaki et al. Life Sciences. 2020. P. 117913. doi: https://doi.org/10.1016/j.lfs.2020.117913